Three out of England’s seven NHS genetics laboratories are failing to routinely share vital information about genetic variants in public databases, a gap that can slow diagnosis and care for patients with rare diseases, according to a BMJ investigation published this week.
The report highlights a problem with practical consequences for clinicians and families who depend on timely genetic interpretation. When variant data is not consistently entered into shared resources, it can make it harder to confirm whether a DNA change is clinically important and whether it may help explain a patient’s symptoms.
Why variant sharing matters for rare disease diagnosis
Rare disease pathways often rely on genetics to provide answers that standard testing cannot. Public databases are used to compare findings across patients and laboratories, helping experts build a clearer picture of whether a variant is benign, uncertain, or disease-causing. In that context, incomplete data sharing can leave some patients waiting longer for a diagnosis or a more precise care plan.
The BMJ’s investigation focuses on NHS genetics laboratories in England and suggests that inconsistent sharing is not a minor administrative issue, but a potential barrier to better care. The report says the missing information is vital for patients with rare diseases seeking diagnosis and treatment support.
A broader challenge for the NHS rare disease pathway
The findings arrive amid continuing pressure on NHS services that support genomic medicine. Better sharing of variant data is increasingly important as testing becomes more central to diagnosing inherited and complex conditions. The investigation suggests that improving routine reporting could strengthen the usefulness of public databases and reduce avoidable delays in clinical decision-making.
For patients and clinicians, the issue is ultimately about speed, certainty, and consistency. A system that shares variant data more reliably would be better placed to turn genetic results into actionable answers, especially when each piece of evidence can matter in a rare disease case.
The BMJ investigation underscores a simple but important point: in rare disease medicine, data that is not shared cannot help the next patient. Addressing that gap could become a meaningful step toward more effective genetic diagnosis across the NHS.
Source reporting on the issue can be found at The BMJ news section, while recent life sciences coverage was also highlighted on News-Medical’s Life Sciences page.
Photo source: AI-generated or edited image
